跳到正文
原文
Nature 综合主刊· Gerhard Krönke·· 23 天前AI 评分19

分子机制与风湿性疾病新治疗概念

Molecular underpinnings of rheumatic diseases and emerging therapeutic concepts

AI 导读

该综述文章探讨了风湿性疾病中的分子机制,并介绍了新兴的治疗概念。研究表明,通过单细胞 RNA 测序分析可以将类风湿关节炎患者分为不同的疾病亚型,有助于指导个体化治疗。

正文
  1. Callahan, L. F. & Pincus, T. Mortality in the rheumatic diseases. Arthritis Rheum. 8, 229–241 (1995).

    CAS  Google Scholar 

  2. Gabriel, S. E. & Michaud, K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res. Ther. 11, 229 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Feldmann, M. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2, 364–371 (2002).

    Article  CAS  PubMed  Google Scholar 

  4. Maini, R. N. & Taylor, P. C. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51, 207–229 (2000).

    CAS  PubMed  Google Scholar 

  5. Weaver, A. L. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology 43, iii17–iii23 (2004).

    PubMed  Google Scholar 

  6. Schett, G., McInnes, I. B. & Neurath, M. F. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N. Engl. J. Med. 385, 628–639 (2021).

    CAS  PubMed  Google Scholar 

  7. McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429–442 (2007).

    Article  CAS  PubMed  Google Scholar 

  8. Tanaka, Y., Luo, Y., O’Shea, J. J. & Nakayamada, S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat. Rev. Rheumatol. 18, 133–145 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Fleischmann, R. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495–507 (2012).

    CAS  PubMed  Google Scholar 

  10. Van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508–519 (2012).

    PubMed  Google Scholar 

  11. Schett, G., Tanaka, Y. & Isaacs, J. D. Why remission is not enough: underlying disease mechanisms in RA that prevent cure. Nat. Rev. Rheumatol. 17, 135–144 (2021).

    Article  PubMed  Google Scholar 

  12. Schett, G. et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann. Rheum. Dis. 75, 1428–1437 (2016).

    CAS  PubMed  Google Scholar 

  13. Haschka, J. et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann. Rheum. Dis. 75, 45–51 (2016). This study demonstrates that tapering therapy results in frequent relapse of disease particularly in patients with ACPA-positive RA.

    PubMed  Google Scholar 

  14. Aringer, M. et al. 2019 EULAR/ACR classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 71, 1400–1412 (2019).

    PubMed  PubMed Central  Google Scholar 

  15. Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569–2581 (2010).

    PubMed  Google Scholar 

  16. Tanaka, H. et al. Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping. Ann. Rheum. Dis. 83, 242–252 (2024).

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Zhang, F. et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature 623, 616–624 (2023). This study shows that single-cell RNA-sequencing-based phenotyping of synovial tissue enables stratification of patients with RA into different disease subtypes.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Robinson, G. A. et al. Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. Lancet Rheumatol. 2, e485–e496 (2020).

    PubMed  PubMed Central  Google Scholar 

  19. Rivellese, F. & Pitzalis, C. Cellular and molecular diversity in rheumatoid arthritis. in Seminars in Immunology, Vol. 58 (eds Rivellese, F. et al.) 101519 (Elsevier, 2021).

  20. Rivellese, F. et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat. Med. 28, 1256–1268 (2022).This trial demonstrates that molecular phenotyping of the synovial tissue ofpatients with RA enables prediction of therapeutic responses.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Rao, D. A. Immune-cell profiling to guide stratification and treatment of patients with rheumatic diseases. Nat. Rev. Rheumatol. 21, 657–670 (2025).

    Article  PubMed  Google Scholar 

  22. Rivellese, F. et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol. 5, e648–e659 (2023).

    CAS  PubMed  Google Scholar 

  23. Lewis, M. J. et al. Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis. Nat. Commun. 16, 5374 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Barturen, G., Beretta, L., Cervera, R., Van Vollenhoven, R. & Alarcón-Riquelme, M. E. Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 14, 75–93 (2018).

    Article  CAS  PubMed  Google Scholar 

  25. Kirino, Y. & Remmers, E. F. Genetic architectures of seropositive and seronegative rheumatic diseases. Nat. Rev. Rheumatol. 11, 401–414 (2015).

    Article  CAS  PubMed  Google Scholar 

  26. Kuiper, J. J. et al. EULAR study group on ‘MHC-I-opathy’: identifying disease-overarching mechanisms across disciplines and borders. Ann. Rheum. Dis. 82, 887–896 (2023).

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Buckley, C. D., Gilroy, D. W., Serhan, C. N., Stockinger, B. & Tak, P. P. The resolution of inflammation. Nat. Rev. Immunol. 13, 59–66 (2013).

    Article  CAS  PubMed  Google Scholar 

  28. Sparks, J. A. & Costenbader, K. H. Genetics, environment, and gene-environment interactions in the development of systemic rheumatic diseases. Rheum. Dis. Clin. North Am. 40, 637–657 (2014).

    PubMed  PubMed Central  Google Scholar 

  29. Clarke, A. & Vyse, T. J. Genetics of rheumatic disease. Arthritis Res. Ther. 11, 248 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  30. Gough, S. C. L., Walker, L. S. K. & Sansom, D. M. CTLA4 gene polymorphism and autoimmunity. Immunol. Rev. 204, 102–115 (2005).

    CAS  PubMed  Google Scholar 

  31. Serrano, N. C., Millan, P. & Páez, M.-C. Non-HLA associations with autoimmune diseases. Autoimmun. Rev. 5, 209–214 (2006).

    CAS  PubMed  Google Scholar 

  32. Begovich, A. B. et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75, 330–337 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Menard, L. et al. The PTPN22allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Invest. 121, 3635–3644 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Schickel, J.-N. et al. PTPN22 inhibition resets defective human central B cell tolerance. Sci. Immunol. 1, aaf7153 (2016).

    PubMed  PubMed Central  Google Scholar 

  35. Adrianto, I. et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat. Genet. 43, 253–258 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Li, W.-W. et al. Tyrosine phosphorylation of IRF3 by BLK facilitates its sufficient activation and innate antiviral response. PLoS Pathog. 19, e1011742 (2023).

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Suzuki, A. et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34, 395–402 (2003).

    Article  CAS  PubMed  Google Scholar 

  38. Al-Mayouf, S. M. et al. Loss-of-function variant in DNASE1L3causes a familial form of systemic lupus erythematosus. Nat. Genet. 43, 1186–1188 (2011).

    Article  CAS  PubMed  Google Scholar 

  39. Kuehn, H. S. et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345, 1623–1627 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Trynka, G. et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat. Genet. 45, 124–130 (2013).

    Article  CAS  PubMed  Google Scholar 

  41. Farh, K. K.-H. et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337–343 (2015). This study demonstrates that the majority of disease-associated genetic variants identified in patients with autoimmune disease can be mapped to immune-cell enhancers.

    Article  CAS  PubMed  Google Scholar 

  42. Calderon, D. et al. Landscape of stimulation-responsive chromatin across diverse human immune cells. Nat. Genet. 51, 1494–1505 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Dörner, T., Jacobi, A. M. & Lipsky, P. E. B cells in autoimmunity. Arthritis Res. Ther. 11, 247 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  44. Kang, E. H., Ha, Y.-J. & Lee, Y. J. Autoantibody biomarkers in rheumatic diseases. Int. J. Mol. Sci. 21, 1382 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  45. van Delft, M. A. M. & Huizinga, T. W. J. An overview of autoantibodies in rheumatoid arthritis. J. Autoimmun. 110, 102392 (2020).

    PubMed  Google Scholar 

  46. Rubin, S. J., Bloom, M. S. & Robinson, W. H. B cell checkpoints in autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 15, 303–315 (2019).

    Article  PubMed  Google Scholar 

  47. Cabral-Marques, O. & Riemekasten, G. Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases. Nat. Rev. Rheumatol. 13, 648–656 (2017).

    Article  CAS  PubMed  Google Scholar 

  48. Jiang, D., Lim, W., Crowther, M. & Garcia, D. A systematic review of the association between anti-β−2 glycoprotein I antibodies and APS manifestations. Blood Adv. 5, 3931–3936 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Ludwig, R. J. et al. Mechanisms of autoantibody-induced pathology. Front. Immunol. 8, 603 (2017).

    PubMed  PubMed Central  Google Scholar 

  50. Rao, D. A. et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature 542, 110–114 (2017).This study identifies an expanded population of potentially disease-relevant expanded population of PD-1hiCXCR5−CD4+ T cells in the inflamed synovial tissue from patients with RA.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Lin, J., Yu, Y., Ma, J., Ren, C. & Chen, W. PD-1+CXCR5−CD4+ T cells are correlated with the severity of systemic lupus erythematosus. Rheumatology 58, 2188–2192 (2019).

    CAS  PubMed  Google Scholar 

  52. Donado, C. A. et al. Granzyme K activates the entire complement cascade. Nature 641, 211–221 (2025).This study shows that GZMK-expressing T cells drive complement activation in inflamed synovial tissue of patients with RA.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Malmström, V., Venalis, P. & Albrecht, I. T cells in myositis. Arthritis Res. Ther. 14, 230 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  54. Scherer, H. U., Huizinga, T. W. J., Krönke, G., Schett, G. & Toes, R. E. M. The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nat. Rev. Rheumatol. 14, 157–169 (2018).

    Article  CAS  PubMed  Google Scholar 

  55. Natalini, J. G. et al. Autoantibody seropositivity and risk for interstitial lung disease in a prospective male-predominant rheumatoid arthritis cohort of U.S. veterans. Ann. Am. Thorac. Soc. 18, 598–605 (2021).

    PubMed  PubMed Central  Google Scholar 

  56. Betteridge, Z. & McHugh, N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J. Intern. Med. 280, 8–23 (2016).

    CAS  PubMed  Google Scholar 

  57. Olsen, N. J. & Karp, D. R. Autoantibodies and SLE—the threshold for disease. Nat. Rev. Rheumatol. 10, 181–186 (2014).

    Article  PubMed  Google Scholar 

  58. Pisetsky, D. S. & Lipsky, P. E. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat. Rev. Rheumatol. 16, 565–579 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Lapteva, L. et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 54, 2505–2514 (2006).

    CAS  PubMed  Google Scholar 

  60. Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526–1533 (2003). This study shows that emergence of anti-nuclear auto-antibodies precedes onset of SLE for several years.

    CAS  PubMed  Google Scholar 

  61. van Zanten, A. et al. Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. Ann. Rheum. Dis. 76, 1184–1190 (2017). This study shows that emergence of ACPAs can precede onset of RA for several years.

    PubMed  PubMed Central  Google Scholar 

  62. Pfeifle, R. et al. Regulation of autoantibody activity by the IL-23–TH17 axis determines the onset of autoimmune disease. Nat. Immunol. 18, 104–113 (2017). This study shows that pathogenic T cells can dictate the inflammatory activity of autoantibodies by instructing autoreactive B cells and regulating the extend of antibody glycosylation.

    Article  CAS  PubMed  Google Scholar 

  63. Lu, D. R. et al. T cell–dependent affinity maturation and innate immune pathways differentially drive autoreactive B cell responses in rheumatoid arthritis. Arthritis Rheumatol. 70, 1732–1744 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Hoi, A., Igel, T., Mok, C. C. & Arnaud, L. Systemic lupus erythematosus. Lancet 403, 2326–2338 (2024).

    CAS  PubMed  Google Scholar 

  65. Postal, M. et al. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr. Opin. Immunol. 67, 87–94 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Siegel, C. H. & Sammaritano, L. R. Systemic lupus erythematosus: a review. JAMA 331, 1480–1491 (2024).

    CAS  PubMed  Google Scholar 

  67. Tsao, B. P. The genetics of human systemic lupus erythematosus. Trends Immunol. 24, 595–602 (2003).

    CAS  PubMed  Google Scholar 

  68. Harley, J. B., Kelly, J. A. & Kaufman, K. M. Unraveling the genetics of systemic lupus erythematosus. Springer Semin. Immunopathol. 28, 119–130 (2006).

    CAS  PubMed  Google Scholar 

  69. Brown, G. J. et al. TLR7gain-of-function genetic variation causes human lupus. Nature 605, 349–356 (2022).This study identifies hyperactive variants of TLR7 as major genetic drivers of SLE.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Wolf, C. et al. UNC93B1 variants underlie TLR7-dependent autoimmunity. Sci. Immunol. 9, eadi9769 (2024).

    CAS  PubMed  Google Scholar 

  71. Majer, O., Liu, B., Kreuk, L. S. M., Krogan, N. & Barton, G. M. UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity. Nature 575, 366–370 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Muñoz, L. E., Lauber, K., Schiller, M., Manfredi, A. A. & Herrmann, M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat. Rev. Rheumatol. 6, 280–289 (2010).

    Article  PubMed  Google Scholar 

  73. Dörner, T. & Lipsky, P. E. The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus. Nat. Rev. Rheumatol. 20, 770–782 (2024).

    Article  PubMed  Google Scholar 

  74. Fillatreau, S., Manfroi, B. & Dörner, T. Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat. Rev. Rheumatol. 17, 98–108 (2021).

    Article  CAS  PubMed  Google Scholar 

  75. Sarkar, M. et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal derived interferon kappa. Ann. Rheum. Dis. 77, 1653–1664 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Farkas, L., Beiske, K., Lund-Johansen, F., Brandtzaeg, P. & Jahnsen, F. L. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159, 237–243 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Koffler, D., Agnello, V., Thoburn, R. & Kunkel, H. G. Systemic lupus erythematosus: prototype of immune complex nephritis in man. J. Exp. Med. 134, 169–179 (1971).

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Savarese, E. et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107, 3229–3234 (2006).

    CAS  PubMed  Google Scholar 

  79. Lövgren, T., Eloranta, M.-L., Båve, U., Alm, G. V. & Rönnblom, L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50, 1861–1872 (2004).

    PubMed  Google Scholar 

  80. Rodero, M. P. & Crow, Y. J. Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. J. Exp. Med. 213, 2527–2538 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Goldbach-Mansky, R., Alehashemi, S. & de Jesus, A. A. Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus. Nat. Rev. Rheumatol. 21, 22–45 (2025).

    Article  PubMed  Google Scholar 

  82. Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721–731 (2011).

    CAS  PubMed  Google Scholar 

  83. Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R. & Isenberg, D. A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46, 2673–2677 (2002). This study provides first evidence for the safety and efficacy of B lymphocyte depletion therapy in SLE.

    PubMed  Google Scholar 

  84. Looney, R. J. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580–2589 (2004).

    CAS  PubMed  Google Scholar 

  85. Ostendorf, L. et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N. Engl. J. Med. 383, 1149–1155 (2020). This study provides first evidence for the efficacy of plasma cell depletion therapy in SLE.

    CAS  PubMed  Google Scholar 

  86. Furie, R. A. et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N. Engl. J. Med. 392, 1471–1483 (2025). This large trial confirms that antibody-mediated B cell depletion is an effective treatmet strategy in SLE.

    CAS  PubMed  Google Scholar 

  87. Morand, E. et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 75, 242–252 (2023).

    CAS  PubMed  Google Scholar 

  88. Furie, R. et al. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 69, 376–386 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211–221 (2020). This trial confirms that therapeutic blockade of the type 1 interferon receptor is an effective treatment approach in SLE.

    CAS  PubMed  Google Scholar 

  90. Morand, E., Merola, J. F., Tanaka, Y., Gladman, D. & Fleischmann, R. TYK2: an emerging therapeutic target in rheumatic disease. Nat. Rev. Rheumatol. 20, 232–240 (2024).

    Article  CAS  PubMed  Google Scholar 

  91. Luo, H., Tian, T., Hu, C. & Hao, F. Targeting the cGAS–STING pathway: emerging strategies and challenges for the treatment of inflammatory skin diseases. Front. Pharmacol. 16, 1597443 (2025).

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Matziol, T., Talagayev, V., Weindl, G. & Wolber, G. Structure-guided approaches to modulate endosomal toll-like receptors TLR7, TLR8 and TLR9: advances, challenges and therapeutic promise. Drug Discov. Today 30, 104495 (2025).

    CAS  PubMed  Google Scholar 

  93. Lama, L. et al. Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression. Nat. Commun. 10, 2261 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  94. Scally, S. W. et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J. Exp. Med. 210, 2569–2582 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  95. Raychaudhuri, S. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 44, 291–296 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Holers, V. M. et al. Rheumatoid arthritis and the mucosal origins hypothesis: external protection becomes internal destruction. Nat. Rev. Rheumatol. 14, 542–557 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  97. Klareskog, L., Padyukov, L., Rönnelid, J. & Alfredsson, L. Genes, environment and immunity in the development of rheumatoid arthritis. Curr. Opin. Immunol. 18, 650–655 (2006).

    CAS  PubMed  Google Scholar 

  98. Willemze, A., Trouw, L. A., Toes, R. E. & Huizinga, T. W. The influence of ACPA status and characteristics on the course of RA. Nat. Rev. Rheumatol. 8, 144–152 (2012).

    Article  CAS  PubMed  Google Scholar 

  99. He, Y. et al. A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis. Nat. Commun. 14, 691 (2023).

    Article  CAS  PubMed  Google Scholar 

  100. Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246–251 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Sokolove, J., Zhao, X., Chandra, P. E. & Robinson, W. H. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor. Arthritis Rheum. 63, 53–62 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  102. Nielen, M. M. J. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380–386 (2004).

    PubMed  Google Scholar 

  103. Alivernini, S., Firestein, G. S. & McInnes, I. B. The pathogenesis of rheumatoid arthritis. Immunity 55, 2255–2270 (2022).

    CAS  PubMed  Google Scholar 

  104. Majka, D. S. et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann. Rheum. Dis. 67, 801–807 (2008).

    CAS  PubMed  Google Scholar 

  105. Alivernini, S. et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat. Med. 26, 1295–1306 (2020). This study shows that presence of immune-modulatory synovial macrophages is associated with remission in patients with RA.

    Article  CAS  PubMed  Google Scholar 

  106. Culemann, S. et al. Locally renewing resident synovial macrophages provide a protective barrier for the joint. Nature 572, 670–675 (2019). This study identifies a population of resident synovial macrophages that maintain an anti-inflammatory barrier preventing spontaneous synovial inflammation.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Pap, T., Müller-Ladner, U., Gay, R. E. & Gay, S. Fibroblast biology: role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. Ther. 2, 361 (2000).

    Article  CAS  Google Scholar 

  108. Cowan, M. J. B., Davidson, S., Coles, M. & Buckley, C. D. The role of fibroblasts across inflammation and immunity. Annu. Rev. Pathol. https://doi.org/10.1146/annurev-pathmechdis-080624-105114 (2026).

    Article  PubMed  Google Scholar 

  109. Harre, U. et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J. Clin. Invest. 122, 1791–1802 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  110. Schett, G. & Teitelbaum, S. L. Osteoclasts and arthritis. J. Bone Miner. Res. 24, 1142–1146 (2009).

    PubMed  Google Scholar 

  111. Harre, U. et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat. Commun. 6, 6651 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Burmester, G. R. & Pope, J. E. Novel treatment strategies in rheumatoid arthritis. Lancet 389, 2338–2348 (2017).

    PubMed  Google Scholar 

  113. Edwards, J. C. W. & Cambridge, G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40, 205–211 (2001).

    CAS  PubMed  Google Scholar 

  114. Edwards, J. C. W. & Cambridge, G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6, 394–403 (2006).

    Article  CAS  PubMed  Google Scholar 

  115. An, J., Marwaha, A. & Laxer, R. M. Autoinflammatory diseases: a review. J. Rheumatol. 51, 848–861 (2024).

    PubMed  Google Scholar 

  116. Szekanecz, Z. et al. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat. Rev. Rheumatol. 17, 585–595 (2021).

    Article  CAS  PubMed  Google Scholar 

  117. Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A. & Kolodner, R. D. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome. Nat. Genet. 29, 301–305 (2001). This study identifies mutations in the gene encoding for NLRP3 as causative for a group of inherited autoinflammatory diseases.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Broderick, L. & Hoffman, H. M. IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nat. Rev. Rheumatol. 18, 448–463 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Lamas, A., Faria, R., Marinho, A. & Vasconcelos, C. The mosaic of systemic lupus erythematosus: from autoimmunity to autoinflammation and immunodeficiency and back. Autoimmun. Rev. 23, 103675 (2024).

    CAS  PubMed  Google Scholar 

  120. Ombrello, M. J. et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc. Natl Acad. Sci. USA. 112, 15970–15975 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  121. Nigrovic, P. A. Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis. Proc. Natl Acad. Sci. USA. 112, 15785–15786 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  122. Beck, D. B. et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N. Engl. J. Med. 383, 2628–2638 (2020).This study identifies acquired somatic mutations in UBA1 as causative for VEXAS syndrome.

    CAS  PubMed  PubMed Central  Google Scholar 

  123. Torreggiani, S., Castellan, F. S., Aksentijevich, I. & Beck, D. B. Somatic mutations in autoinflammatory and autoimmune disease. Nat. Rev. Rheumatol. 20, 683–698 (2024).

    Article  PubMed  Google Scholar 

  124. Savola, P., Bhattacharya, D. & Huuhtanen, J. The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty’s syndrome. Semin. Hematol. 59, 123–130 (2022).

    PubMed  Google Scholar 

  125. Pascart, T. et al. Calcium pyrophosphate deposition disease. Lancet Rheumatol. 6, e791–e804 (2024).

    CAS  PubMed  Google Scholar 

  126. Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).

    Article  CAS  PubMed  Google Scholar 

  127. Pascual, V., Allantaz, F., Arce, E., Punaro, M. & Banchereau, J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201, 1479–1486 (2005).

    CAS  PubMed  PubMed Central  Google Scholar 

  128. Schlesinger, N. Anti-interleukin-1 therapy in the management of gout. Curr. Rheumatol. Rep. 16, 398 (2014).

    Article  PubMed  Google Scholar 

  129. Lachmann, H. J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416–2425 (2009). This study shows the clinical efficacy of IL-1 blockade as approach in the treatment of inherited autoinflammatory diseases.

    CAS  PubMed  Google Scholar 

  130. Weber, A. N. R. et al. The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets. Nat. Immunol. 26, 1453–1466 (2025).

    Article  CAS  PubMed  Google Scholar 

  131. Coll, R. C. et al. A small molecule inhibitior of the NLRP3 inflammasome is a potential therapeutic for inflammatory diseases. Nat. Med. 21, 248–255 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Leung, Y. Y., Yao Hui, L. L. & Kraus, V. B. Colchicine–update on mechanisms of action and therapeutic uses. Semin. Arthritis Rheum. 45, 341–350 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Liu, Z. et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct. Target. Ther. https://doi.org/10.1038/s41392-023-01451-2 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  134. Shaw, A. C., Goldstein, D. R. & Montgomery, R. R. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13, 875–887 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Salvarani, C., Pipitone, N., Versari, A. & Hunder, G. G. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat. Rev. Rheumatol. 8, 509–521 (2012).

    Article  CAS  PubMed  Google Scholar 

  136. Hiitola, E. et al. Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes. Sci. Adv. 11, eadt9846 (2025).

    CAS  PubMed  PubMed Central  Google Scholar 

  137. Wu, H., Wei, J., Yu, Y., Wang, N. & Tan, X. Clonal hematopoiesis of indeterminate potential and the risk of autoimmune diseases. J. Intern. Med. 297, 642–656 (2025).

    CAS  PubMed  PubMed Central  Google Scholar 

  138. Uchiyama, S. et al. Mosaic loss of chromosome Y characterises late-onset rheumatoid arthritis and contrasting associations of polygenic risk score based on age at onset. Ann. Rheum. Dis. 84, 1313–1323 (2025).

    CAS  PubMed  Google Scholar 

  139. Shiomi, M. et al. Uncovering the new biology of giant cell arteritis to guide therapeutic strategies. J. Clin. Med. 14, 6350 (2025).

    CAS  PubMed  PubMed Central  Google Scholar 

  140. Petzinna, S. M. et al. AYLo study-elevated relapse risk and dysregulated proinflammatory signalling in giant cell arteritis patients with mosaic loss of the Y chromosome. Ann. Rheum. Dis. 84, 1900–1908 (2025).

    CAS  PubMed  Google Scholar 

  141. Ji, J., Liu, X., Sundquist, K., Sundquist, J. & Hemminki, K. Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology 49, 1158–1163 (2010).

    PubMed  Google Scholar 

  142. Kim, H.-H. & Dixit, V. D. Metabolic regulation of immunological aging. Nat. Aging 5, 1425–1440 (2025).

    Article  PubMed  Google Scholar 

  143. Weyand, C. M. & Goronzy, J. J. Immune aging in rheumatoid arthritis. Arthritis Rheumatol. 77, 792–804 (2025).

    CAS  PubMed  PubMed Central  Google Scholar 

  144. Zheng, Y., Liu, Q., Goronzy, J. J. & Weyand, C. M. Immune aging—a mechanism in autoimmune disease. Semin. Immunol. 69, 101814 (2023).

    CAS  PubMed  PubMed Central  Google Scholar 

  145. Shive, C. & Pandiyan, P. Inflammation, immune senescence, and dysregulated immune regulation in the elderly. Front. Aging 3, 840827 (2022).

    PubMed  PubMed Central  Google Scholar 

  146. Bonelli, M. et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. Ann. Rheum. Dis. 81, 838–844 (2022).

    CAS  PubMed  Google Scholar 

  147. Tomelleri, A. et al. Disease stratification in GCA and PMR: state of the art and future perspectives. Nat. Rev. Rheumatol. 19, 446–459 (2023).

    Article  CAS  PubMed  Google Scholar 

  148. Stone, J. H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317–328 (2017).

    CAS  PubMed  Google Scholar 

  149. Queiro, R., Morante, I., Cabezas, I. & Acasuso, B. HLA-B27 and psoriatic disease: a modern view of an old relationship. Rheumatology 55, 221–229 (2016).

    CAS  PubMed  Google Scholar 

  150. Brewerton, D. A. et al. Ankylosing spondylitis and HL-A27. Lancet 1, 904–907 (1973).

    CAS  PubMed  Google Scholar 

  151. Yang, X. et al. Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides. Nature 612, 771–777 (2022). This study identifies autoreactive T cell receptors that cross-react to self- and microbial-derived peptides presented by HLA-B27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Paley, M. A. et al. Mucosal signatures of pathogenic T cells in HLA-B*27+ anterior uveitis and axial spondyloarthritis. JCI Insight 9, e174776 (2024).

    PubMed  PubMed Central  Google Scholar 

  153. McGonagle, D., Gibbon, W. & Emery, P. Classification of inflammatory arthritis by enthesitis. Lancet 352, 1137–1140 (1998).

    CAS  PubMed  Google Scholar 

  154. McGonagle, D. et al. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum. 41, 694–700 (1998). This study identifies enthesitis as common hallmark of spondylarthropathies.

    CAS  PubMed  Google Scholar 

  155. Benjamin, M. et al. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum. 56, 224–233 (2007).

    CAS  PubMed  Google Scholar 

  156. Sherlock, J. P. et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+CD3+CD4−CD8− entheseal resident T cells. Nat. Med. 18, 1069–1076 (2012).

    Article  CAS  PubMed  Google Scholar 

  157. Bridgewood, C., Sharif, K., Sherlock, J., Watad, A. & McGonagle, D. Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy. Immunol. Rev. 294, 27–47 (2020).

    CAS  PubMed  Google Scholar 

  158. Ono, T. et al. IL-17-producing γδ T cells enhance bone regeneration. Nat. Commun. 7, 10928 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  159. Ciccia, F. et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 60, 955–965 (2009).

    CAS  PubMed  Google Scholar 

  160. Jo, S. et al. IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis. Arthritis Res. Ther. 20, 115 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  161. Łukasik, Z., Gracey, E., Venken, K., Ritchlin, C. & Elewaut, D. Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints. Rheumatology 60, iv16–iv27 (2021).

    PubMed  PubMed Central  Google Scholar 

  162. Wellcome Trust Case Control Consortium & The Australo-Anglo-American Spondylitis Consortium (TASC). Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 39, 1329–1337 (2007).

    Article  Google Scholar 

  163. Rahman, P. et al. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum. 58, 1020–1025 (2008).

    CAS  PubMed  Google Scholar 

  164. Villalpando-Vargas, F. V. et al. Association between IL-17A, IL-17F and IL-17RA gene polymorphisms and susceptibility to psoriasis and psoriatic arthritis: a meta-analysis. Inflamm. Res. 70, 1201–1210 (2021).

    Article  CAS  PubMed  Google Scholar 

  165. Deodhar, A. et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395, 1115–1125 (2020).

    CAS  PubMed  Google Scholar 

  166. Tsukazaki, H. & Kaito, T. The role of the IL-23/IL-17 pathway in the pathogenesis of spondyloarthritis. Int. J. Mol. Sci. 21, 6401 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  167. Baeten, D. et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373, 2534–2548 (2015).

    CAS  PubMed  Google Scholar 

  168. Hotamisligil, G. S. Inflammation, metaflammation and immunometabolic disorders. Nature 542, 177–185 (2017).

    Article  CAS  PubMed  Google Scholar 

  169. Haberman, R. H., Ogdie, A., Merola, J. F., Scher, J. U. & Eder, L. The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies. Nat. Rev. Rheumatol. 22, 151–164 (2026).

    Article  CAS  PubMed  Google Scholar 

  170. Merola, J. F. et al. Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial. Arthrits Rheum. https://doi.org/10.1002/art.70134 (2026).

    Article  Google Scholar 

  171. Donath, M. Y. & Drucker, D. J. Obesity, diabetes, and inflammation: pathophysiology and clinical implications. Immunity 58, 2373–2382 (2025).

    CAS  PubMed  Google Scholar 

  172. Gokce, M. et al. The impact of liraglutide, a GLP-1 receptor agonist, on high glucose-induced inflammation, apoptosis, oxidative stress, and NLRP3 signaling. Cell Biochem. Biophys. 83, 3619–3632 (2025).

    Article  CAS  PubMed  Google Scholar 

  173. Hench, P. S., Kendall, E. C., Slocumb, C. H. & Polley, H. F. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report. Ann. Rheum. Dis. 8, 97–104 (1949).

    CAS  PubMed  PubMed Central  Google Scholar 

  174. Eiers, A.-K., Vettorazzi, S. & Tuckermann, J. P. Journey through discovery of 75 years glucocorticoids: evolution of our knowledge of glucocorticoid receptor mechanisms in rheumatic diseases. Ann. Rheum. Dis. 83, 1603–1613 (2024).

    CAS  PubMed  Google Scholar 

  175. Auger, J.-P. et al. Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids. Nature 629, 184–192 (2024). This study shows that the anti-inflammatory effects of glucocorticoids are linked to a mitochondrial reprogramming of immune cells.

    Article  CAS  PubMed  Google Scholar 

  176. Furie, R. A. et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology 60, 5397–5407 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  177. Moreland, L. W. et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46, 1470–1479 (2002).

    CAS  PubMed  Google Scholar 

  178. Ruderman, E. M. Overview of safety of non-biologic and biologic DMARDs. Rheumatology 51, vi37–vi43 (2012).

    PubMed  Google Scholar 

  179. van der Heijde, D. et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann. Rheum. Dis. 82, 515–526 (2023).

    CAS  PubMed  PubMed Central  Google Scholar 

  180. McInnes, I. B. et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet 401, 25–37 (2023).

    CAS  PubMed  Google Scholar 

  181. Dömling, A. & Holak, T. A. Balinatunfib: a clinical oral small molecule TNFα inhibitor. ChemMedChem. 20, e202500258 (2025).

    PubMed  PubMed Central  Google Scholar 

  182. Bissonnette, R. et al. Oral icotrokinra for plaque psoriasis in adults and adolescents. N. Engl. J. Med. 393, 1784–1795 (2025).

    CAS  PubMed  Google Scholar 

  183. Ramirez-Perez, S. et al. MyD88 dimerization inhibitor ST2825 targets the aggressiveness of synovial fibroblasts in rheumatoid arthritis patients. Arthritis Res. Ther. 25, 180 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  184. Ringheim, G. E., Wampole, M. & Oberoi, K. Bruton’s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. Front. Immunol. 12, 662223 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  185. Edmondson, S. D. Discovery of the first clinical protein degrader for the treatment of autoimmune indications: orally bioavailable and selective IRAK4 degrader KT-474. J. Med. Chem. 67, 18017–18021 (2024).

    CAS  PubMed  Google Scholar 

  186. Brenke, J. K. et al. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. J. Biol. Chem. 293, 13191–13203 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  187. Jimenez-Sanchez, S., Maksoud, R., Eaton-Fitch, N., Marshall-Gradisnik, S. & Broadley, S. A. The role of alemtuzumab in the development of secondary autoimmunity in multiple sclerosis: a systematic review. J. Neuroinflammation 21, 281 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  188. Tuttle, J. et al. A phase 2 trial of peresolimab for adults with rheumatoid arthritis. N. Engl. J. Med. 388, 1853–1862 (2023).

    CAS  PubMed  Google Scholar 

  189. Britanova, O. V. et al. Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis. Nat. Med. 29, 2731–2736 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  190. Furie, R. A. et al. Efficacy and safety of obinutuzumab in active systemic lupus erythematosus. N. Engl. J. Med. 392, 1471–1483 (2025).

    CAS  PubMed  Google Scholar 

  191. Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 64, 1215–1226 (2012).

    CAS  PubMed  Google Scholar 

  192. Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222–233 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  193. Kamburova, E. G. et al. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am. J. Transplant. 13, 1503–1511 (2013).

    CAS  PubMed  Google Scholar 

  194. Alexander, T. & Greco, R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 57, 1055–1062 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  195. van Laar, J. M. et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311, 2490–2498 (2014).

    PubMed  Google Scholar 

  196. Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567–569 (2021). The first case report demonstrating the efficacy of CD19 CAR-T cells in a patient with refractory SLE.

    PubMed  Google Scholar 

  197. Alexander, T., Krönke, J., Cheng, Q., Keller, U. & Krönke, G. Teclistamab-induced remission in refractory systemic lupus erythematosus. N. Engl. J. Med. 391, 864–866 (2024).

    PubMed  Google Scholar 

  198. Tur, C. et al. Effects of different B-cell-depleting strategies on the lymphatic tissue. Ann. Rheum. Dis. 84, 2065–2074 (2025).

    CAS  PubMed  Google Scholar 

  199. Siegert, E. et al. Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation. Ann. Rheum. Dis. 84, 653–656 (2025).

    CAS  PubMed  Google Scholar 

  200. Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124–2132 (2022).

    Article  CAS  PubMed  Google Scholar 

  201. Hagen, M. et al. BCMA-targeted T-cell-engager therapy for autoimmune disease. N. Engl. J. Med. 391, 867–869 (2024).

    PubMed  Google Scholar 

  202. Minopoulou, I. et al. Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis. Ann. Rheum. Dis. 84, e4–e7 (2025).

    CAS  PubMed  Google Scholar 

  203. Wilhelm, A. et al. Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE. JCI Insight 9, e179433 (2024).

    PubMed  PubMed Central  Google Scholar 

  204. Müller, F. et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with Follow-up. N. Engl. J. Med. 390, 687–700 (2024). A case series illustrating the capacity of CD19 CAR-T cells to induce a sustained drug free remission in SLE.

    PubMed  Google Scholar 

  205. Müller, F. et al. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial. Nat. Med. https://doi.org/10.1038/s41591-025-04185-6 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  206. Junt, T. et al. Defining immune reset: achieving sustained remission in autoimmune diseases. Nat. Rev. Immunol. 25, 528–541 (2025).

    Article  CAS  PubMed  Google Scholar 

  207. Albach, F. N. et al. CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial. Nat. Med. 32, 3862–3873 (2026).

  208. Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179–184 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  209. Oh, S. et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat. Biotechnol. 41, 1229–1238 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

来源:Nature 综合主刊 · nature.com